ALKERMES | ALKS - Selling And Administration Expenses

Stock Price
33.31
Daily Change
-0.60 -1.77%
Monthly
13.42%
Yearly
19.65%
Q2 Forecast
32.32

ALKERMES reported $187.2M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
ALKERMES USD 187.2M 15.43M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
J&J USD 6.03B 719M Mar/2026
Malin Corporation EUR 1.1M 400K Dec/2024
Merck USD 2.85B 215M Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Otsuka Holdings JPY 278.3B 24.08B Dec/2025
Ovoca Bio EUR 632K 2.33M Jun/2025
Pfizer USD 4.08B 894M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025